Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study
出版年份 2017 全文链接
标题
Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study
作者
关键词
-
出版物
Orthopaedic Surgery
Volume 9, Issue 1, Pages 103-109
出版商
Wiley
发表日期
2017-03-09
DOI
10.1111/os.12307
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club
- (2016) E. Cavalier et al. OSTEOPOROSIS INTERNATIONAL
- Bone Health and Osteoporosis
- (2015) Beatrice C. Lupsa et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)
- (2015) Dennis M. Black et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Projection of osteoporosis-related fractures and costs in China: 2010–2050
- (2015) L. Si et al. OSTEOPOROSIS INTERNATIONAL
- Efficacy and Safety of Single-Dose Zoledronic Acid for Osteoporosis in Frail Elderly Women
- (2015) Susan L. Greenspan et al. JAMA Internal Medicine
- Risk of Atypical Femoral Fracture during and after Bisphosphonate Use
- (2014) Jörg Schilcher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Calcium Supplementation: Is Protecting Against Osteoporosis Counter to Protecting against Cardiovascular Disease?
- (2014) Connie M. Weaver Current Osteoporosis Reports
- RANKL Inhibition With Denosumab Does Not Influence 3-Year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosis and High Cardiovascular Risk
- (2013) Elizabeth J Samelson et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Understanding and Communicating the Benefits and Risks of Denosumab, Raloxifene, and Teriparatide for the Treatment of Osteoporosis
- (2013) E. Michael Lewiecki et al. JOURNAL OF CLINICAL DENSITOMETRY
- A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures
- (2013) L. Si et al. OSTEOPOROSIS INTERNATIONAL
- Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday
- (2012) Michael McClung et al. AMERICAN JOURNAL OF MEDICINE
- Five years of anti-resorptive activity after a single dose of zoledronate — Results from a randomized double-blind placebo-controlled trial
- (2012) Andrew Grey et al. BONE
- Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy
- (2012) Cherie Ying Chiang et al. BONE
- Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management
- (2012) Kurt A. Kennel et al. MAYO CLINIC PROCEEDINGS
- Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis
- (2012) K. Ganda et al. OSTEOPOROSIS INTERNATIONAL
- European guidance for the diagnosis and management of osteoporosis in postmenopausal women
- (2012) J. A. Kanis et al. OSTEOPOROSIS INTERNATIONAL
- Rapidly increasing rates of hip fracture in Beijing, China
- (2011) Wei-Bo Xia et al. JOURNAL OF BONE AND MINERAL RESEARCH
- The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
- (2011) Dennis M Black et al. JOURNAL OF BONE AND MINERAL RESEARCH
- GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates
- (2011) P. Hadji et al. OSTEOPOROSIS INTERNATIONAL
- Spinal Trauma in Mainland China From 2001 to 2007
- (2011) Peng Liu et al. SPINE
- Osteoporosis treatments and adverse events
- (2009) Daniel H Solomon et al. CURRENT OPINION IN RHEUMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation